Next 10 |
home / stock / cmxhf / cmxhf news
2024-04-24 08:31:26 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics gains as EU backs kidney disease therapy Travere Therapeutics Q4...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...
2024-03-07 09:19:59 ET More on CSL CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgrade) CSL Limited (CSLLY) Q2 2024 Earnings Call Transcript CSL Limited falls after Phase 3 setback for key trial Historical earnings data for CSL ...
2024-02-13 15:00:58 ET Summary CSL Limited achieved a +3% earnings beat for 1H FY 2024, and the company's full-year FY 2024 financial guidance was left unchanged. But CSL Limited's CSL112 trial results were unfavorable, which suggests that there might be an absence of meaningful p...
2024-02-13 00:53:08 ET CSL Ltd (CSLLY) Q2 2024 Earnings Conference Call February 12, 2024, 19:00 ET Company Participants Mark Dehring - Head, IR Paul McKenzie - MD, CEO & Executive Director William Mezzanotte - EVP & Head, Research and Development Her...
2024-02-12 13:53:40 ET More on CSL CSL Limited: Positive Capital Return And Earnings Growth Expectations Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan Historical earnings data for CSL Dividend scorecard for CSL ...
2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...
News, Short Squeeze, Breakout and More Instantly...
Csl Ltd Company Name:
CMXHF Stock Symbol:
OTCMKTS Market:
New York, United States (ABN Newswire) - OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX:CSL) (OTCMKTS:CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicine...
HATTERSHEIM AM MAIN, Germany , Jan. 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza® as standard treatment for ...